This study is looking at how well and how safely a medication called solriamfetol works for teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD). You might be able to join if you are 12 to 17 years old and have been diagnosed with ADHD. Participants will receive either solriamfetol at one of two different doses, or a placebo (an inactive pill that looks like the study drug). The main goal is to see if solriamfetol can improve ADHD symptoms, measured by a specific rating scale, after 6 weeks. The study plans to enroll 468 participants, but its current status is unclear.

Study design

This is a Phase 3, randomized, double-blind study, meaning participants are randomly assigned to a treatment group and neither you nor your doctor will know which treatment you are receiving. It involves about 468 participants.

What's involved

You would take a capsule once daily for 6 weeks. Your parents or legal guardians would need to give written permission, and you would also need to agree to participate.

Compensation

Not stated in the trial record.

Follow-up

The main assessment for the study is at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.